Teva's SD-809 passes latest tardive dyskinesia test

14:27 EDT 22 Sep 2016 | BioCentury

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said two doses of SD-809 deutetrabenazine met the primary endpoint in the Phase III AIM-TD study to treat moderate to severe tardive dyskinesia. The company intends to submit an NDA to FDA for SD-809 by year end.

The 288-patient trial evaluated 12, 24 and 36 mg doses of SD-809 vs. placebo, and measured improvements in Abnormal Involuntary Movement Scale (AIMS) from baseline to 12 weeks. The high and middle doses improved baseline scores by 3.3 and 3.2 points, respectively, vs. 1.4 points for placebo (p=0.001 for the high dose and p=0.003 for the middle dose). The low dose improved scores by 2.1 points, which was non-significant vs. placebo.

Teva said the frequency of adverse events was similar among all treatment groups, and said SD-809's safety profile was consistent with previous studies.

In June 2015, SD-809 met the primary endpoint of improving AIMS scores in the Phase II/III ARM-TD study to treat moderate to severe tardive dyskinesia (see BioCentury Extra, June 16, 2015).

SD-809 is a deuterium-substituted analog of tetrabenazine, a vesicular monoamine transporter 2 (VMAT2; SLC18A2) inhibitor. Teva gained the candidate via its May 2015 acquisition of Auspex Pharmaceuticals Inc. (see BioCentury, April 6, 2015).

SD-809 has breakthrough therapy designation for tardive dyskinesia. It has Orphan Drug designation in Huntington's disease (HD) and Tourette's syndrome in patients aged 16 and younger. In May, Teva received a complete response letter from FDA for SD-809 to treat chorea associated with HD. Spokesperson Doris Saltkill said the company plans to respond to FDA this quarter on the CRL (see BioCentury Extra, May 31).

An NDA for competing VMAT2 inhibitor Ingrezza valbenazine (NBI-98854) from Neurocrine Biosciences Inc. (NASDAQ:NBIX) is under FDA review to treat tardive dyskinesia. Last year, Neurocrine said an 80 mg dose of Ingrezza significantly improved AIMS scores by 3.1 points more than placebo from baseline to six weeks, meeting the primary endpoint in a Phase III study's intent-to-treat population (see BioCentury Extra, Oct. 8, 2015).

Original Article: Teva's SD-809 passes latest tardive dyskinesia test


More From BioPortfolio on "Teva's SD-809 passes latest tardive dyskinesia test"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...